In contrast, although the CLK2 protein was not associated with sensitivity to T‐025 in hematological cancer cell lines (Fig EV3C), we found that T‐025 showed profound anti‐tumor efficacies in xenografts in an MV‐4‐11 AML cell line (Fig EV3D), which was one of the most sensitive hematological cancer cell lines in the panel (IC50 = 30.1 nmol/l), as well as in xenografts derived from AML patient (PDX) (Fig EV3E). This evidence concerns the gene CLK2 and hematopoietic and lymphoid cell neoplasm.